Boston Scientific sees Q1 electives rebound, hints at further 2021 M&A

Boston Scientific sees Q1 electives rebound, hints at further 2021 M&A

Source: 
Medtech Dive
snippet: 

Boston Scientific grew organic sales by 5.9% in the first quarter of 2021 to $2.75 billion, beating the previous guidance range between negative 3% and 3% in the quarter due to the pressures from the coronavirus pandemic.